Smith & Nephew Plc
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Smith & Nephew Plc - overview
Established
1856
Location
London, England, UK
Primary Industry
Medical Devices & Equipment
About
Smith & Nephew Plc is a global medical technology company specializing in advanced solutions for the repair, regeneration, and replacement of soft and hard tissue, serving healthcare professionals and institutions worldwide. Founded in 1856 in London, UK by Sydney Stafford, Smith & Nephew Plc focuses on developing innovative medical technologies. The company has not undergone notable pivots in its strategy or operations and maintains multiple global offices. Currently, Smith & Nephew is led by a management team including Deborah Madonini, Deepak Nath, Michael Störk, Roland Diggelmann, and Stefano Marchese.
Smith & Nephew's product offerings include advanced medical technologies across Orthopaedics, Sports Medicine, ENT, and Advanced Wound Management. Their Orthopaedics segment features innovative hip and knee implants, alongside robotics-assisted technologies. Sports Medicine includes instruments for minimally invasive soft tissue surgeries, while the Advanced Wound Management segment provides solutions for acute and chronic wound care. Their products are primarily distributed in the United States, Europe, and Asia-Pacific, targeting hospitals and surgical centers.
For the fiscal year 2024, Smith & Nephew reported revenue of USD 7,425. 86 mn and an EBITDA of USD 1,513. 29 mn. The company generates revenue through direct sales and partnerships, focusing on B2B sales within healthcare facilities.
Smith & Nephew aims to expand its product line with new offerings in the Orthopaedics and Advanced Wound Management segments, focusing on innovating surgical tools and wound care technologies. They are also targeting expansion into emerging markets in Asia and Latin America by 2025, utilizing their recent funding to support product development and market entry strategies.
Primary Industry
Medical Devices & Equipment
Sub Industries
Medical Devices & Equipment
Website
www.smith-nephew.com
Total Amount Raised
Subscriber access only
Smith & Nephew Plc - timeline of key events
Smith & Nephew Plc - financials
| Fiscal Year Ended | Dec 31, 2010 | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 3,962,000,000 | 4,270,000,000 | 4,137,000,000 | 4,351,000,000 | 4,617,000,000 | 4,634,000,000 | 4,669,000,000 | 4,765,000,000 | 4,904,000,000 | 5,138,000,000 | 4,560,000,000 | 5,212,000,000 | - | - | - |
| % Revenue Growth (YoY) | - | 7.8% | (3.1%) | 5.2% | 6.1% | 0.4% | 0.8% | 2.1% | 2.9% | 4.8% | (11.2%) | 14.3% | - | - | - |
| EBITDA (USD) | 1,193,000,000 | 1,157,000,000 | 1,152,000,000 | 1,171,000,000 | 1,162,000,000 | 1,073,000,000 | 1,216,000,000 | 1,369,000,000 | 1,290,000,000 | 1,311,000,000 | 840,000,000 | 1,160,000,000 | - | - | - |
| Operating Income (USD) | 920,000,000 | 862,000,000 | 846,000,000 | 810,000,000 | 749,000,000 | 628,000,000 | 801,000,000 | 934,000,000 | 863,000,000 | 815,000,000 | 295,000,000 | 593,000,000 | - | - | - |
| Operating Margin | 23.2% | 20.2% | 20.4% | 18.6% | 16.2% | 13.6% | 17.2% | 19.6% | 17.6% | 15.9% | 6.5% | 11.4% | - | - | - |
| % EBITDA Margin | 30.1% | 27.1% | 27.8% | 26.9% | 25.2% | 23.2% | 26.0% | 28.7% | 26.3% | 25.5% | 18.4% | 22.3% | - | - | - |
| NET Income (USD) | 615,000,000 | 582,000,000 | 729,000,000 | 556,000,000 | 501,000,000 | 410,000,000 | 784,000,000 | 767,000,000 | 663,000,000 | 600,000,000 | 448,000,000 | 524,000,000 | - | - | - |
| % Net Margin | 15.5% | 13.6% | 17.6% | 12.8% | 10.9% | 8.8% | 16.8% | 16.1% | 13.5% | 11.7% | 9.8% | 10.1% | - | - | - |
Smith & Nephew Plc - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Completed | Integrity Orthopaedics, Inc. | - | ||||||||
| Series B | Completed | Miach Orthopaedics, Inc. | - | ||||||||
| Trade Sale | Completed | CartiHeal, Inc. | - | ||||||||
| Series B | Completed | Miach Orthopaedics, Inc. | - | ||||||||
| Add-on | Completed | Misonix Inc | - |
Displaying 1 - 5 of 8
Smith & Nephew Plc - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.